Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Depreciation & Amortization (CF) (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $904000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 4.44% year-over-year to $904000.0; the TTM value through Sep 2025 reached $3.7 million, down 5.45%, while the annual FY2024 figure was $3.8 million, 7.78% up from the prior year.
  • Depreciation & Amortization (CF) reached $904000.0 in Q3 2025 per SNTI's latest filing, down from $914000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q3 2023 and bottomed at $200000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $703764.7, with a median of $904000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 237.0% in 2023, then dropped 29.82% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $269000.0 in 2021, then soared by 68.03% to $452000.0 in 2022, then skyrocketed by 119.47% to $992000.0 in 2023, then decreased by 5.54% to $937000.0 in 2024, then fell by 3.52% to $904000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $904000.0 in Q3 2025, $914000.0 in Q2 2025, and $926000.0 in Q1 2025.